Short‐Course of Oral Miltefosine for Treatment of Visceral Leishmaniasis
Open Access
- 1 October 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (4) , 1110-1113
- https://doi.org/10.1086/318122
Abstract
A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; grouKeywords
This publication has 8 references indexed in Scilit:
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- Oral treatment of visceral leishmaniasis with miltefosinePathogens and Global Health, 1999
- Trial of oral miltefosine for visceral leishmaniasisThe Lancet, 1998
- Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first line drug? An observational study of 80 casesPathogens and Global Health, 1998
- Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India Commentary: Some good news for treatment of visceral leishmaniasis in BiharBMJ, 1998
- Short-Course, Low-Dose Amphotericin B Lipid Complex Therapy for Visceral Leishmaniasis Unresponsive to AntimonyAnnals of Internal Medicine, 1997
- A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumoursZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Meaningful clinical classification of therapeutic responses to anticancer drugsClinical Pharmacology & Therapeutics, 1961